T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Background The outcome of older patients with B-cell acute lymphocytic leukaemia is
inferior to that in younger patients due to the adverse disease biology and their inability to …

Background Blinatumomab is effective in relapsed or refractory B-cell acute lymphocytic
leukaemia and results in high rates of minimal residual disease negativity. We aimed to …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

PURPOSE Despite recent advances in adapting the intensity of treatment for older patients
with ALL, current protocols are associated with high rates of early deaths, treatment-related …

Novel treatment strategies are needed for the treatment of Philadelphia chromosome–
positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients. This trial evaluated the …

Blinatumomab is an efficacious immunotherapeutic agent in B cell acute lymphoblastic
leukemia (B-ALL). However, the pharmacogenomic basis of leukemia response to …

Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory
Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia …

Background Older adults are a large and growing proportion of cancer cases in the United
States, but concerns persist about whether older adults are adequately represented in the …